Comparing the current results to its competitors, Myriad Genetics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -10.39 %, despite the revenue increase by the most of its competitors of 17.58 %, recorded in the same quarter.
Myriad Genetics Inc 's Comment on Competition and Industry Peers
The company operates in a market alongside Genomind, Tempus AI, Inc., Quest Diagnostics Incorporated, and Laboratory Corporation of America Holdings. Its test aims to improve patient response rates compared to standard care. Growth opportunities include increasing awareness of pharmacogenomic options for mental health treatment and promoting physician adoption through digital engagement and provider onboarding programs, focusing on primary care and behavioral health clinicians treating depression and anxiety.
September 3, 2025
: Recent research published in the Journal of Clinical Psychopharmacology has unveiled compelling evidence regarding the efficacy of the GeneSight pharmacogenomic test in optimizing antidepressant response and remission rates among patients with major depressive disorder. This meta-analysis consolidates findings from multiple studies, revealing that integrating genetic insights into clinical decision-making can significantly elevate therapeutic outcomes for individuals struggling with depression. This article seeks to provide a comprehensive overview of the implications of this pivotal research, emphasizing the role of pharmacogenomics in personalized medicine.Depression remains a pervasive global health c...
October 15, 2024
In a groundbreaking move poised to reshape the landscape of healthcare, Myriad Genetics, a leader in genetic testing and innovative diagnostics, has announced a strategic partnership with Flatiron Health, a frontrunner in oncology data and software solutions. This collaboration aims to democratize access to genetic testing through seamless integration with electronic medical records (EMRs), marking a significant milestone in personalized medicine.As genetic testing continues to evolve, its role in informing treatment options and guiding patient care has never been more crucial. However, many patients still face hurdles in accessing these vital tests due to logistical challenges and fragmented healthcare syst...
October 3, 2024
In a pivotal move that could reshape the landscape of genetic testing, Myriad Genetics, a prominent player in precision medicine, has announced a strategic collaboration with Ultima Genomics, a company on the cutting edge of next-generation sequencing (NGS) technology. This partnership aims to leverage Ultima s UG 100 sequencing platform, which promises ultra-high throughput capabilities and innovative ppmSeq technology, to enhance clinical testing offerings in oncology and reproductive genomics.This alliance was officially unveiled on October 3, 2024, and marks a significant milestone for both companies. Myriad Genetics has notably secured a UG 100 sequencer, which will soon be integrated into its advanced ...
May 23, 2024
Cancer treatment has witnessed significant advancements in recent years, largely owing to diagnostic tools such as molecular residual disease (MRD) testing. MRD testing has revolutionized cancer care by enabling early detection of cancer recurrence and tailoring treatment plans for individual patients. Myriad Genetics, a leading molecular diagnostics company, presented cutting-edge research and innovative product developments at the 2024 ASCO Annual Meeting, showcasing their dedication to advancing cancer care.Molecular Residual Disease (MRD) Study and RiskScore Studies:Myriad Genetics introduced their latest MRD study at the ASCO Annual Meeting, along with multiple RiskScore studies. This MRD study, along w...
April 16, 2024
A remarkable scientific study spearheaded by Myriad Genetics, Inc., a pioneering front-runner in genetic testing and precision medicine, has been recently published in Prenatal Diagnosis. This groundbreaking study illustrates the superior Positive Predictive Value (PPV) for 22q11.2 microdeletion syndrome screening via Myriad s innovative prenatal cell-free DNA (pcfDNA) screen, dubbed as Prequel.Renowned worldwide for their exceptional contributions to genetic testing, Myriad Genetics continues to push boundaries in their quest for enhanced prenatal screenings. The feat of developing a successful predictive model for 22q11.2 microdeletion syndrome, a rare chromosomal disorder, underpins their commitment to th...
February 27, 2024
In a remarkable collaboration between Myriad Genetics and the National Cancer Center Hospital East in Japan, the stage is set for a transformative clinical trial: SCRUM-MONSTAR-SCREEN-3. This innovative study aims to revolutionize the way we monitor minimal residual disease (MRD) across various cancer types. Central to this trial is the utilization of Myriad s cutting-edge Precise MRD test, enabling researchers to evaluate the wide-ranging applicability of MRD testing.The groundbreaking SCRUM-MONSTAR-SCREEN-3 clinical trial marks a significant milestone in the fight against cancer. Myriad Genetics, a pioneering molecular diagnostics company, has partnered with the esteemed National Cancer Center Hospital Eas...
In an era where genetic testing and precision medicine have revolutionized healthcare, Myriad Genetics, Inc. (NASDAQ: MYGN) stands out as a leader in the field. The company recently celebrated a significant milestone, as it announced delivering results to one million consumers with its SneakPeek Early Gender DNA Test. This groundbreaking test has been providing expectant families with an easy and convenient way to learn the sex of their baby as early as six weeks into pregnancy. Myriad Genetics has been at the forefront of genetic testing and precision medicine since its establishment. The SneakPeek Early Gender DNA Test is a testament to the company s commitment to innovation and addressing the nee...
Adaptive Biotechnologies Corporation is a biotechnology company that utilizes its proprietary immune medicine platform to decode and analyze the human immune system. Their business model focuses on providing solutions for the diagnosis, monitoring, and treatment of various diseases such as cancer and infectious diseases. By leveraging genomics and machine learning technologies, they aim to create personalized immunotherapies and diagnostics to improve patient outcomes.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Interpace Biosciences Inc operates upon a business model that involves providing molecular diagnostic tests and services for improved patient management and outcomes.
Prenetics Global Limited is a company that operates in the field of personalized healthcare by offering genetic testing services to individuals. The company partners with healthcare providers and insurance companies to provide insights and recommendations based on genetic information, aiming to empower individuals to make informed decisions about their health.
Sources:
Myriad Genetics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Myriad Genetics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
